Codiak BioSciences Inc. announced the appointment of Benny Sorensen, M.D., Ph.D., as Vice President and Head of Clinical Development. Dr. Sorensen serves on the executive leadership team, reporting to Douglas E. Williams, Ph.D., President and CEO. In this new position, Dr. Sorensen will lead clinical drug-development and medical strategy. Dr. Sorensen joined the company from Alnylam Pharmaceuticals, where he was Senior Director of Clinical Research since 2013 leading preclinical as well as clinical, regulatory, medical affairs and commercial development strategies for hematology products. He has more than 15 years of experience in clinical and translational research and management. Before joining Alnylam, Dr. Sorensen was a Global Medical Director at Baxter Healthcare Corporation advancing phase three pivotal development of Adynovate and Vonvendi. Prior to Baxter he was the Director of the Haemostasis Research Unit and Honorary Lecturer at Guy's and St. Thomas' Hospital & King'sCollege London School of Medicine, where he led basic translational research and advancement of several clinical trials across Phases I, II, and III. Dr. Sorensen has published extensively in hematology translational and clinical research.